Adaptive Biotechnologies is Biotechnology in United States that focus on Adaptive Biotechnologies Corp business. Founded in 2009. They cover business area such as Adaptive Biotechnologies Corp, immune-drive medicine, treatment, disease, its clinical diagnostic product, clonoSEQ, monitoring, patient, select blood cancer.
2009
( 15 years old in 2024 )
Adaptive Biotechnologies Corp
-
1551 Eastlake Avenue East
Suite 200
Seattle, WA 98102
United States
Private
Adaptive Biotechnologies Corpimmune-drive medicinetreatmentdiseaseits clinical diagnostic productclonoSEQmonitoringpatientselect blood cancer
* We use standard office opening hours in near Adaptive Biotechnologies's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Adaptive Biotechnologies is Biotechnology business from United States that founded in 2009 (15 years old in 2024), Adaptive Biotechnologies business is focusing on Adaptive Biotechnologies Corp.
Adaptive Biotechnologies headquarter office and corporate office address is located in 1551 Eastlake Avenue East Suite 200 Seattle, WA 98102 United States.
Adaptive Biotechnologies was founded in United States.
In 2024, Adaptive Biotechnologies is currently focus on Adaptive Biotechnologies Corp sector.
Above is snippet of Google Trends for "Adaptive Biotechnologies Corp" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Adaptive Biotechnologies, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.